Innova Captab Q2 FY27 Results: Consolidated Net Profit ₹42.42 Crore on Total Income of ₹499 Crore
- Earnings
- Pharmaceuticals

Innova Captab (NSE: INNOVACAP) reported consolidated total income of ₹498.76 crore and consolidated net profit of ₹42.42 crore for the quarter ended 30 Sep 2026. Standalone total income was ₹407.68 crore and standalone net profit ₹31.97 crore, it said in a filing on 13 Nov 2026.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹498.76 crore, up 29.7% YoY and 5.5% QoQ
- Net profit and EPS: ₹42.42 crore, up 43.0% YoY and down 3.9% QoQ; basic EPS ₹7.41
- Finance costs: ₹4.27 crore, down 22.3% YoY and 3.6% QoQ
Standalone
The company on its own, without its subsidiaries
- Total income: ₹407.68 crore, up 38.4% YoY and 1.1% QoQ
- Net profit and EPS: ₹31.97 crore, up 123.0% YoY and down 0.3% QoQ; basic EPS ₹5.59
- Finance costs: ₹3.95 crore, down 24.1% YoY and 2.0% QoQ
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 498.76 | 384.57 | +29.7% | 472.86 | +5.5% | |
| Revenue from operations | 496.30 | 380.38 | +30.5% | 470.85 | +5.4% |
| Other income | 2.46 | 4.19 | -41.2% | 2.01 | +22.8% |
| 42.42 | 29.67 | +43.0% | 44.13 | -3.9% | |
| Profit before tax | 56.30 | 39.24 | +43.5% | 58.99 | -4.6% |
| Finance costs | 4.27 | 5.50 | -22.3% | 4.43 | -3.6% |
| Depreciation | 11.84 | 11.32 | +4.5% | 11.71 | +1.1% |
| Tax expense | 13.88 | 9.57 | +45.1% | 14.86 | -6.6% |
| Net profit margin | 8.51% | 7.72% | +0.79 pp | 9.33% | -0.83 pp |
| EPS, basic (₹) | 7.41 | 5.18 | +43.1% | 7.71 | -3.9% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than total income over the year. Consolidated net profit rose 43.0% to ₹42.42 crore while total income rose 29.7%, and profit before tax rose 43.5%. Revenue from operations, at ₹496.30 crore, rose 30.5%, while other income fell 41.2% to ₹2.46 crore. Other income is 0.5% of total income this quarter, so the growth comes almost entirely from operations.
Against the previous quarter the picture reverses. Total income rose 5.5% but net profit fell 3.9% to ₹42.42 crore from ₹44.13 crore, and tax expense fell 6.6%. Tax expense of ₹13.88 crore is 24.6% of profit before tax of ₹56.30 crore. The filing does not give a reason for the change in deferred tax between the periods.
Finance costs of ₹4.27 crore are 0.9% of total income, and depreciation of ₹11.84 crore rose 4.5% year on year, so neither is large against revenue.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 407.68 | 294.46 | +38.4% | 403.18 | +1.1% | |
| Revenue from operations | 404.78 | 289.83 | +39.7% | 400.48 | +1.1% |
| Other income | 2.90 | 4.63 | -37.4% | 2.70 | +7.3% |
| 31.97 | 14.33 | +123.0% | 32.06 | -0.3% | |
| Profit before tax | 42.02 | 19.27 | +118.1% | 43.03 | -2.4% |
| Finance costs | 3.95 | 5.21 | -24.1% | 4.03 | -2.0% |
| Depreciation | 9.89 | 9.48 | +4.4% | 9.68 | +2.2% |
| Tax expense | 10.05 | 4.94 | +103.7% | 10.97 | -8.4% |
| Net profit margin | 7.84% | 4.87% | +2.97 pp | 7.95% | -0.11 pp |
| EPS, basic (₹) | 5.59 | 2.50 | +123.6% | 5.60 | -0.2% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone profit rose far faster than income. Net profit rose 123.0% to ₹31.97 crore from ₹14.33 crore, against total income growth of 38.4%. Profit before tax rose 118.1% to ₹42.02 crore, and tax expense rose 103.7% to ₹10.05 crore, so the tax rate moved from about 25.6% to 23.9%.
Standalone net profit was almost flat against the previous quarter, down 0.3% from ₹32.06 crore, while total income rose 1.1%. Other income of ₹2.90 crore is 6.9% of profit before tax of ₹42.02 crore.
The company has one reportable segment, drugs and pharmaceutical products. The statutory auditors expressed an unmodified review conclusion on both sets of results. The auditors did not review the financial information of one subsidiary, which had nil revenue and a net profit after tax of ₹0.16 million for the quarter before consolidation adjustments; another auditor reviewed it.
The company's market value is ₹6,709 crore at the 13 Nov 2026 close of ₹1,172.40 a share. The latest quarter reported on Blacklitt, Q1 FY27, showed consolidated total income of ₹472.86 crore and net profit of ₹44.13 crore.
Inference
The board approved the unaudited results on 13 Nov 2026, and the results are available on the company's website and on the stock exchange websites. The filing does not give a reason for the rise in total income and profit against the year-earlier quarter, or for the rise in other expenses and employee benefits expense.
The filing does not say whether the rise in profit will continue in later quarters, and it gives no dividend or capital plan for the period.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

